Pamela J. Weathers, a Professor in Biology and Biotechnology at Worcester Polytechnic Institute received her Ph.D. from Michigan State University Plant Research Lab in 1974 and has ~50 yrs experience working on plants, roots, algae, and bioreactor development. She is an internationally recognized expert on Artemisia annua and artemisinin, having worked with the plant and its phytochemicals including the antimalarial drug, artemisinin, for >30 years. Her long-term goal is the development of Artemisia as a sustainable, cost-effective Botanical Drug for treating a variety of infectious diseases including tuberculosis and Covid-19. She is a Fellow of AAAS and SIVB, won many research and entrepreneurial awards, given many national and international presentations, reviewed manuscripts for many journals and proposals for many national and international funding agencies. She is an Associate Editor of multiple journals. Her lab was the first to genetically transform A. annua.
As of 2026 she has >140 peer-reviewed papers; about a third focus on bioreactors and more than half on artemisinin or A. annua, and more recently, A. afra. She also has 3 patents (3 more pending). Her Google H-index is 53, her i10 is 115, with > 9,900 citations. She spearheaded the translational edible A. annua concept for treating covid-19, malaria, TB and other diseases and has led research to establish proof-of-concept. obtained significant funding from NSF, NASA, NIH, USDA, and the private sector.
Pamela J. Weathers, a Professor in Biology and Biotechnology at Worcester Polytechnic Institute received her Ph.D. from Michigan State University Plant Research Lab in 1974 and has ~50 yrs experience working on plants, roots, algae, and bioreactor development. She is an internationally recognized expert on Artemisia annua and artemisinin, having worked with the plant and its phytochemicals including the antimalarial drug, artemisinin, for >30 years. Her long-term goal is the development of Artemisia as a sustainable, cost-effective Botanical Drug for treating a variety of infectious diseases including tuberculosis and Covid-19. She is a Fellow of AAAS and SIVB, won many research and entrepreneurial awards, given many national and international presentations, reviewed manuscripts for many journals and proposals for many national and international funding agencies. She is an Associate Editor of multiple journals. Her lab was the first to genetically transform A. annua.
As of 2026 she has >140 peer-reviewed papers; about a third focus on bioreactors and more than half on artemisinin or A. annua, and more recently, A. afra. She also has 3 patents (3 more pending). Her Google H-index is 53, her i10 is 115, with > 9,900 citations. She spearheaded the translational edible A. annua concept for treating covid-19, malaria, TB and other diseases and has led research to establish proof-of-concept. obtained significant funding from NSF, NASA, NIH, USDA, and the private sector.